May Hill Capital LLC boosted its holdings in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 88.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 8,546 shares of the company's stock after acquiring an additional 4,021 shares during the quarter. May Hill Capital LLC's holdings in AstraZeneca were worth $628,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently bought and sold shares of AZN. Capital International Investors raised its holdings in shares of AstraZeneca by 1.9% during the fourth quarter. Capital International Investors now owns 37,507,159 shares of the company's stock valued at $2,457,706,000 after acquiring an additional 686,008 shares during the period. Bank of America Corp DE raised its position in AstraZeneca by 189.3% during the fourth quarter. Bank of America Corp DE now owns 24,026,966 shares of the company's stock valued at $1,574,247,000 after buying an additional 15,722,197 shares during the period. Franklin Resources Inc. increased its holdings in shares of AstraZeneca by 1.9% in the 4th quarter. Franklin Resources Inc. now owns 19,480,569 shares of the company's stock valued at $1,276,367,000 after purchasing an additional 357,894 shares during the period. Sanders Capital LLC lifted its position in AstraZeneca by 1.4% in the 4th quarter. Sanders Capital LLC now owns 15,186,692 shares of the company's stock worth $995,032,000 after buying an additional 212,301 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in shares of AstraZeneca by 13.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 5,322,388 shares of the company's stock worth $348,730,000 after acquiring an additional 636,537 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors.
AstraZeneca Price Performance
NASDAQ AZN opened at $69.63 on Tuesday. AstraZeneca PLC has a twelve month low of $61.24 and a twelve month high of $87.68. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.70 and a current ratio of 0.90. The stock has a market capitalization of $215.94 billion, a PE ratio of 27.96, a P/E/G ratio of 1.28 and a beta of 0.37. The stock has a 50-day simple moving average of $70.77 and a 200 day simple moving average of $70.71.
AstraZeneca (NASDAQ:AZN - Get Free Report) last released its earnings results on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, beating the consensus estimate of $1.10 by $0.14. The firm had revenue of $13.59 billion during the quarter, compared to analysts' expectations of $13.71 billion. AstraZeneca had a net margin of 14.14% and a return on equity of 33.14%. The business's quarterly revenue was up 7.2% compared to the same quarter last year. During the same period in the prior year, the company earned $2.06 EPS. Research analysts anticipate that AstraZeneca PLC will post 4.51 EPS for the current year.
Wall Street Analyst Weigh In
Separately, BNP Paribas started coverage on shares of AstraZeneca in a research report on Tuesday, April 15th. They set an "outperform" rating and a $75.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, AstraZeneca presently has a consensus rating of "Moderate Buy" and a consensus target price of $85.00.
Check Out Our Latest Analysis on AZN
About AstraZeneca
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Featured Stories
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
